SafePath Laboratories, LLC

SafePath Laboratories, LLC, based in the US, specializes in developing and marketing high-performance immunoassays, focusing on veterinary diagnostic test kits to enhance animal health outcomes. SafePath Laboratories, LLC is engaged in the development and manufacture of diagnostic test kits for veterinary applications. Founded in 1995 by Dave Lambillotte, the company is headquartered in Carlsbad, US. It has completed one major deal, with the most recent transaction occurring in December 2025, when KVP International, Inc.

, a portfolio company of Carmelina Capital Partners, acquired SafePath Laboratories, LLC. Financial terms of the transaction were not disclosed. SafePath Laboratories, LLC specializes in the development, manufacture, and marketing of high-performance immunoassays, particularly diagnostic test kits for veterinary applications. Their core product offerings include the Canine Giardia Antigen Test and the Canine Parvovirus Antigen Test, designed to detect specific pathogens in canine patients.

These products are essential for veterinary practices, enabling timely diagnoses for dogs and improving animal health outcomes. The client base primarily consists of veterinary clinics, animal hospitals, and diagnostic laboratories, with products available in North America, Europe, and parts of Asia. SafePath Laboratories generates revenue through the sale of diagnostic test kits to veterinary professionals and institutions. These transactions typically occur on a B2B basis, allowing veterinary clinics and laboratories to order products to meet their diagnostic needs.

The company maintains direct partnerships with veterinary distributors and wholesalers, facilitating broader access to its offerings. Pricing plans for flagship products such as the Canine Giardia Antigen Test and the Canine Parvovirus Antigen Test are competitive for bulk orders, accommodating both small practices and larger veterinary chains, thereby ensuring a steady flow of transactions with clients. Looking ahead, SafePath Laboratories is set to utilize the resources from its acquisition by KVP International, Inc. to expand its research and development capabilities.

With the completion of the acquisition in December 2025, the company aims to enhance its product offerings and may introduce new diagnostic tests in the veterinary market. The expansion strategy involves targeting new geographical regions, enabling greater access to its products, although specific markets for this expansion have not been disclosed.